Lifeline Biotechnologies, Inc. Prepares to Update Web site with Current Company Information

RENO, Nev.--(BUSINESS WIRE)--Lifeline Biotechnologies, Inc. (Pink Sheets:LLBT) announced today that it is preparing to update its Web site with detailed Company information in order to provide up-to-date information that is readily available to the public.

Lifeline is focused on completing the development of the First Warning System™, designed to assist in the early detection of breast cancer. The underlying technology, upon which the First Warning System™ is based, holds the possibility of eliminating over 90% of unnecessary breast biopsies performed each year providing a potential savings of up to $2.8 billion annually. The First Warning System™ could conceivably eliminate the need for suggested MRIs, a savings of another $1.3 billion.

“We are in the process of providing Company information on our Web site as a supplement or alternative to Pink Sheets. The information will be comprehensive and will be updated often to provide current information available to the public,” stated Jim Holmes, CEO of Lifeline Biotechnologies, Inc.

To find out more information about Lifeline Biotechnologies, Inc., please visit: www.lbti.com.

About Lifeline Biotechnologies, Inc:

Lifeline Biotechnologies, Inc. is an innovative medical technology company committed to the improvement of the quality of life through exceptional health care systems, focusing on prevention, early diagnosis, and quick recovery. The Company is focused on completing the development of the First Warning System™, designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually, assuming the following are successfully completed: the development of the First Warning System™, the completion of clinical trials and FDA pre-marketing clearance.

The Company competes in the money markets for funds to support its First Warning System™ development. In the past, equity funding terms have been expensive and dilutive to common stock shareholders. Future fundings may dilutive.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact:

Lifeline Biotechnologies, Inc.
Investor Relations 
1-886-THE APPL(E)
www.lbti.com

Source: Lifeline Biotechnologies, Inc.